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A2B ADENOSINE RECEPTOR MODULATION OF TNF-ALPHA EXPRESSION 
IN MOUSE RHEUMATOID ARTHRITIS 
CAROLINE M. CIOCCA 
ABSTRACT 
 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to 
destruction of articular cartilage and subchondral bone at the synovial joints. Clinically, 
RA is characterized by swelling, tenderness and destruction of synovial joints, which 
results in severe disability and premature mortality. In the RA disease state, inflammation 
in the synovial compartment is regulated by a complex cytokine and chemokine network, 
including tumor necrosis factor α (TNFα), which has been clinically demonstrated a key 
mediator of RA pathogenesis. TNFα can be found in elevated levels in the synovial fluid 
and serum of RA patients and the role of the cytokine in both the inflammation and bone 
destruction of RA suggests it is important in the understanding of disease progression as 
well as the development of therapeutic targets. Many of the biological processes that 
mediate RA, including bone turnover and cartilage resorption, involve signaling 
pathways that are mediated by adenosine and its receptors. The A2B adenosine receptor 
(A2BAR) is highly expressed in the synoviocytes of RA patients and the receptor has a 
similar expression profile in humans and mice. The goal of this thesis was to use a mouse 
model of RA to understand how the A2B adenosine receptor modulates TNFα and other 
destructive enzymes that contribute to the progression of the disease.  
A collagen antibody-induced arthritis (CAIA) mouse model was used to 
determine the effect of A2BAR ablation on systemic and joint-specific TNFα expression. 
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Comparable arthritic conditions were observed in CAIA mice of both A2BAR knockout 
(KO) and wild-type (WT) genotypes and the absence of the A2BAR gene did not result in 
any observable differences in the gross arthritic state created in each genotype. 
Immunohistochemistry analysis of TNFα expression in mouse paws revealed that paw 
joints from CAIA A2BAR KO mice exhibited more robust TNFα staining compared to 
CAIA WT specimens of the same treatment duration. ELISA analysis of the serum 
showed that only CAIA A2BAR KO mice had greater serum production of TNFα at day 
10 after induction of arthritis. TNFα and matrix metalloproteinase-9 mRNA expression 
were also elevated in KO CAIA knee joints in comparison to WT CAIA knee joints; 
however, WT CAIA mice were found to have higher levels of aggrecanase mRNA 
compared to KO mice. These results suggest that while the loss of A2BAR activity leads 
to a hyper-inflammatory state, the A2B adenosine receptor alone is not responsible for the 
progressive inflammation of the synovial joints associated with rheumatoid arthritis. 
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INTRODUCTION 
Epidemiology of Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that 
leads to destruction of articular cartilage and subchondral bone at the synovial joints. 
Clinically, RA is characterized by swelling, tenderness and destruction of synovial joints, 
which results in severe disability and premature mortality (Aletaha et al. 2010). RA 
affects between 0.5% and 1.0% of the population, with women accounting for more 
diagnosed cases than men (Kelsey and Hochberg 1988; Gabriel 2001). Individuals with a 
family history of RA have three to five times the risk of developing the disease and 
concordance rates in twins are increased, implicating genetic factors in pathogenesis 
(Smolen, Aletaha, and McInnes 2016). There are more than a hundred loci associated 
with RA risk and most implicate immune mechanisms (Smolen, Aletaha, and McInnes 
2016). The HLA system, particularly HLA-DRB1, remains the dominant genetic 
influence, making the genetic basis of RA similar to that of other chronic autoimmune 
diseases like multiple sclerosis (Smolen, Aletaha, and McInnes 2016). Increased risk for 
RA is found in patients with seropositivity for autoantibodies against IgG, such as 
rheumatoid factor. The characteristic autoantibodies for RA are present in 50-70% of 
patients at diagnosis and can be detected throughout the disease course (Smolen, Aletaha, 
and McInnes 2016). 
Epigenetics contribute to the pathogenesis of RA through the combination of 
environmental and genetic effects. A recent study identified ten differentially methylated 
positions that could promote genetic risk in RA (Liu et al. 2013). Changes in histone 
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acetylation and DNA methylation can modify the biology of synovial fibroblasts and 
leucocytes (Klein and Gay 2015). Environmental risk factors for RA include smoking, 
low socioeconomic status and lack of education (Pincus and Sokka 2001). 
The musculoskeletal damage caused by RA leads to a decline in physical function 
and a severely decreased quality of life. Although RA is not a direct cause of death, RA 
patients do have increased mortality compared to healthy controls (Gabriel 2001; Pincus 
and Sokka 2001). Due to the pain associated with RA, 35% of RA patients are unable to 
work within 10 years of disease onset and inability to work contributes greatly to the 
societal costs of RA (Allaire et al. 2008). Decreased work capacity and other indirect 
costs account for 52% of the costs of RA (McIntosh 1996). Medical care and other direct 
costs account for 48% of the costs of the disease (McIntosh 1996). 
Rheumatoid Arthritis Pathology 
RA is pathologically heterogeneous, however the presence of autoantibodies, such 
as autoantibodies against citrullinated peptides (ACPAs) and rheumatoid factor (RF), are 
associated with more severe symptoms, joint damage and increased mortality (Smolen, 
Aletaha, and McInnes 2016). ACPAs can be detected up to ten years before RA diagnosis 
and articular involvement (Smolen, Aletaha, and McInnes 2016). ACPAs are pathogenic 
by activating macrophages, osteoclasts and other bone loss pathways (Harre et al. 2012). 
Effective therapy can result in a decrease in both RF and ACPA concentrations, but while 
patients may become seronegative for RF, it is rare for patients to become ACPA 
negative (Böhler et al. 2013). RF is more directly involved in mechanisms of macrophage 
activation and induction of cytokine activation than ACPAs. 
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Joint swelling in RA is the result of synovial membrane inflammation 
characterized by leucocyte infiltration of the synovial compartment (Figure 1). The cells 
involved in synovitis include innate immune cells (monocytes, dendritic cells, mast cells, 
innate lymphoid cells) and adaptive immune cells (T-helper-1 and T-helper-17 cells, B 
cells, plasmablasts and plasma cells) (Smolen, Aletaha, and McInnes 2016). 
Inflammatory synovial fibroblasts, combined with enhanced chondrocyte catabolism and 
synovial osteoclastogenesis, are responsible for the articular destruction observed in RA 
(McInnes and Schett 2011). 
 
 
 
 
 
 
 
 
 
 
Inflammation in the synovial compartment is regulated by a complex cytokine and 
chemokine network, including tumor necrosis factor α (TNFα) and interleukin 6 (IL-6), 
that has been clinically demonstrated as key to RA pathogenesis (Marc Feldmann and 
Figure 1. Diagram showing A) a healthy synovial joint and B) a synovial joint 
displaying the damage of rheumatoid arthritis (Smolen and Steiner 2003). 
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Maini 2008). TNFα, a key mediator of immune response, and IL-6, another pro-
inflammatory cytokine, are both present in elevated levels in the synovial fluid and serum 
of RA patients (Firestein et al. 1990; Okamoto et al. 1997). In vivo, TNFα is the most 
rapidly produced pro-inflammatory cytokine, with serum levels detectable in mice within 
30 minutes of injury or infection (M. Feldmann and Maini 2001). Both cytokines have 
also been found to contribute to the differentiation of osteoclasts, the cells that resorb 
bone tissue (Lam et al. 2000; Kudo et al. 2003). TNFα and IL-6 induce an inflammatory 
response by activating endothelial cells and signaling immune cells to accumulate within 
the synovial compartment (Figure 2) (Smolen, Aletaha, and McInnes 2016). Activated 
fibroblasts, T cells and B cells express RANKL, which interacts with the RANK receptor 
on macrophages, dendritic cells and pre-osteoclasts to trigger osteoclast generation 
(Redlich and Smolen 2012). Bony erosions then arise at the junction between the 
cartilage, the periosteal synovial membrane and the bone, resulting in cartilage damage 
(Smolen, Aletaha, and McInnes 2016). Matrix metalloproteinases and other enzymes 
cause further cartilage matrix degradation (Martel-Pelletier, Welsch, and Pelletier 2001).  
The role of cytokines in both the inflammation and bone destruction of RA 
suggests they are important in the understanding of disease progression as well as the 
development of therapeutic targets. Although many current therapies do target cytokines, 
further study of the receptors that activate these cytokines may yield new targets for 
novel RA therapies.  
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Current Therapeutic Targets 
 Inflammation is one of the fundamental cause of joint damage in RA and 
therefore the primary target of many current therapies. While over-the-counter anti-
inflammatory drugs may be effective in ameliorating the symptoms of RA, disease-
modifying therapies (DMTs) are also capable of reducing the progression of structural 
joint damage. Biological DMTs, mostly in the form of monoclonal antibodies, have been 
developed to target many key inflammatory factors, including TNFα. When the release of 
TNFα is blocked, it has been found that the expression of other pro-inflammatory 
Figure 2. Overview of 
pathways involved in TNFα 
and IL-1 signaling. Pro-
inflammatory cytokines 
TNFα and IL-1 activate two 
pathways, NF-κΒ (left) and 
the MAPK pathway (right). 
The NF-κΒ pathway leads 
to the activation of genes 
coding for cytokines, 
chemokines, anti-apoptotic 
and stress proteins. The 
MAPK pathway induces 
activation of genes coding 
for various cytokines 
(including TNFα and IL-1) 
and other inflammatory 
molecules including 
prostaglandins, proteases 
and matrix 
metalloproteinases (Smolen 
and Steiner 2003). 
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cytokines is also reduced (M. Feldmann and Maini 2001). When treated with a TNFα 
inhibitor, transgenic mice that were overexpressing the cytokine developed less severe 
arthritis (Keffer et al. 1991). In humans, drugs that block TNFα activity can lead to 
diminished disease progression and improved physical function, however, only half of 
the patients that take TNF inhibitors experience the reported benefits (Figure 3) (M. 
Feldmann and Maini 2001; Moreland et al. 1999). Despite the key role TNFα plays in the 
generation of inflammation and joint destruction characteristic of RA, the lack of a 
definitive response in all patients to anti-TNF drugs suggests that interrupting the 
function of one inflammatory factor is not sufficient (Smolen and Steiner 2003). If 
progress is to be made in the treatment of RA, a better understanding of the relevant 
inflammatory factors and their interactions is imperative. 
 
Figure 3. Efficacy of etanercept, a competitive TNF inhibitor, versus placebo. Data 
points represent the percent of patients who achieved at least 20% improvement on 
clinical assessment per American College of Rheumatology criteria. Patients were 
treated with one of two etanercept doses, 25 mg (triangle) or 10 mg (square), or 
placebo (circle) (Moreland et al. 1999). 
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A2B Adenosine Receptor 
Many of the biological processes that mediate RA, including bone turnover, 
cartilage resorption and angiogenesis, are driven by inflammation and involve signaling 
pathways that are mediated by adenosine, a purine nucleoside, and its receptors. 
Adenosine receptors are a family of G-protein coupled receptors that are ubiquitously 
expressed throughout the body. There are four receptor subtypes: A1, A2A, A2B, A3, and it 
is common for more than one type of adenosine receptor to be expressed on a single cell 
type. This pattern of expression suggests there are likely interactions between the 
different adenosine receptors (Yaar et al. 2005). 
Although in vivo studies of adenosine receptor function provide limited ability to 
study the specific functions of each receptor, mouse models created to overexpress or not 
express a specific adenosine receptor have generated important insights into the function 
of each receptor subtype (Yaar et al. 2005). These studies have found that the A1 and A3 
receptors inhibit adenylate cyclase and decrease the production of cAMP (Yaar et al. 
2005). In contrast, the A2A and A2B receptors stimulate adenylate cyclase and increase the 
production of cAMP (Yaar et al. 2005). The two A2 receptors are distinguished by the 
high adenosine affinity of A2A and the low adenosine affinity of A2B (Yaar et al. 2005). 
Due to its low adenosine affinity, the A2B adenosine receptor (A2BAR) tends to be 
activated only at high, pathological adenosine levels like those found in rheumatoid 
arthritis (Yaar et al. 2005). A2BAR is highly expressed in the synoviocytes of RA patients 
and the receptor has a similar expression profile in humans and mice (Puffinbarger et al. 
1995). 
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The expression patterns of adenosine receptors suggest that they play a role in the 
inflammatory processes of RA that ultimately lead to bone destruction. A2BAR activation 
results in the release of pro-inflammatory cytokines from neutrophils and monocytes 
(Stamp et al. 2012). In one study, A2BAR KO mice had increased TNFα levels following 
lipopolysaccharide (LPS) treatment compared to wild-type mice, indicating that A2BAR 
inhibits TNFα release (Yang et al. 2006). In contrast, another study found that treatment 
of cultured macrophages with N-ethylcarboxamidoadenosine (NECA), a general 
adenosine receptor agonist, stimulates interleukin-6 (IL-6) release, but suppresses the 
release of LPS-induced TNFα in wild-type mice (Ryzhov et al. 2008). The inhibitory 
effect of NECA was even greater in A2BAR KO mice, suggesting that A2B receptors are 
not involved in adenosine-dependent suppression of LPS-induced TNFα release from 
macrophages (Figure 4) (Ryzhov et al. 2008). This same study found that A2BAR KO 
mice to have increased basal and LPS-stimulated TNFα release from macrophages and 
higher TNFα plasma levels (Ryzhov et al. 2008). In light of conflicting evidence in the 
literature, studying A2BAR in a knockout system could lead to identification of novel 
therapeutic targets for RA.  
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Modulation of A2BAR may have downstream effects on other pathways leading to 
destructive changes in RA. TNFα promotes osteoclastogenesis via RANK-L, while IL-6 
and IL-11 promote osteoclastogenesis via a RANK-L independent pathway (Lam et al. 
2000; Kudo et al. 2003). IL-1 induces production of matrix metalloproteinases (MMPs), 
which contribute to cartilage resorption (D. L. Boyle, Sajjadi, and Firestein 1996). 
Adenosine receptors, including A2BAR, have also been found to mediate the production 
of MMPs. Adenosine deaminase (ADA) is an enzyme that catalyzes the irreversible 
conversion of adenosine to inosine, reducing adenosine levels. RA patients have 
increased ADA activity, which is correlated with an increased MMP-9 concentration 
(Iwaki-Egawa, WatanabeY, and Matsuno 2001). In fibroblast-like synoviocytes 
stimulated by IL-1, NECA reduces production of MMP-1 and MMP-3 that is typically 
Figure 4. Effect of A2B receptor gene ablation on TNFα plasma levels and 
secretion from peritoneal macrophages. WT and A2B KO mice were injected with 
NECA+LPS or LPS alone then plasma concentrations of TNFα were measured. 
Data are presented as the mean ± S.E.M. of five animals per group. Asterisks 
indicate statistical difference from LPS values (***, p < 0.001) (Ryzhov et al. 
2008). 
	10 
induced by IL-1, but agonists specific to A1, A2A and A3 do not produce the same effect 
(D. L. Boyle et al. 1997). The study that produced these results was performed before the 
identification of an A2B-specific agonist and therefore indirectly demonstrates how the 
reduction of MMP production is mediated by the A2B adenosine receptor. Identification 
of an A2BAR-specific agonist, BAY 60-6583, allowed the direct demonstration of the 
relationship between A2BAR and MMP-9 production in a model of vascular injury. This 
led to the discovery that ablation of the A2BAR in activated macrophages results in 
increased MMP-9 production (Chen et al. 2011). In combination, the results of these 
studies characterize the role of the A2B adenosine receptor in the degradation of cartilage 
in RA (Table 1).  
A2BAR may also directly influence bone turnover, cartilage resorption and 
angiogenesis. Upregulation of A2BAR in osteoprogenitor cells and differentiating 
osteoblasts indicates that A2BAR also directly affects bone cells (Evans et al. 2006; Costa 
et al. 2011). Stimulation of the A2BAR in osteoprogentitor cells is associated with 
increased mineralization and expression of osteoblastic markers such as ALP, 
osteocalcin, Runx2 and osterix (Carroll et al. 2012; Gharibi et al. 2011; Trincavelli et al. 
2014). The stimulation of A2BAR was also found to inhibit osteoprotegrin (OPG), which 
itself is an inhibitor of osteoblastogenesis, leading to overall reduced OPG/RANKL ratios 
(Evans et al. 2006).  
A2BAR has also been found to play a role in the metabolism of the overlaying 
synovial cartilage. Stimulation of A2BAR suppresses MMP production in vitro, while 
MMP-9 expression is upregulated in A2BAR KO mice with vascular injury (D. L. Boyle, 
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Sajjadi, and Firestein 1996; Chen et al. 2011). A2BAR may also contribute to the 
progression of RA through its influence over vascularization of the pannus. In a study of 
polymorphonuclear neutrophils, treatment with TNFα induced release of vascular 
endothelial growth factor (VEGF), a stimulator of angiogenesis. The same study found 
treatment with adenosine resulted in the inhibition of VEGF release (Wakai et al. 2001). 
In contrast, treatment of endothelial cells with adenosine agonists and antagonists 
indicated instead that the A2BAR stimulates VEGF release (Feoktistov et al. 2002). The 
divergent and at times conflicting conclusions regarding the role of A2BAR in the 
vascularization of the pannus ultimately allude to the complexity of A2BAR’s influence 
on RA pathogenesis. 
 
 
Table 1. Summary of effects of A2BAR agonists and antagonists on different cell types 
found at synovial joints (D. L. Boyle, Sajjadi, and Firestein 1996; Chen et al. 2011; 
Evans et al. 2006; Carroll et al. 2012; Costa et al. 2011; Wakai et al. 2001; Feoktistov 
et al. 2002). 
 
Cell Type Effect of A2BAR Agonist Effect of A2BAR Antagonist 
Osteoprogenitor Cells ↑ Bone mineralization  
↑ Expression of 
osteoblastic markers 
↓	OPG  
-- 
Synoviocytes ↓	MMP production in vitro ↑ MMP-9 production 
Polymorphonuclear 
neutrophils 
↓	VEGF release -- 
Endothelial cells ↑ VEGF release -- 
Macrophages -- ↑ MMP-9 production 
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Animal Models for Rheumatoid Arthritis 
The understanding of RA pathology and the development of effective therapeutics 
have been greatly advanced by the use of animal models of the disease. An early model 
of RA involved injecting Freund’s adjuvant rats and mice with type II collagen, the 
primary collagen found in cartilage (Trentham, Townes, and Kang 1977). Mice injected 
with type II collagen display an autoimmune response similar to RA, including swollen 
paws and histological evidence of pannus development leading to eventual bone and 
cartilage erosion (Courtenay et al. 1980). Used in mouse knock-out strains, this collagen-
induced arthritis (CIA) model offered the potential to elucidate the roles of specific 
genes, but it was soon discovered that certain knock-out strains are more susceptible to 
CIA than others (Courtenay et al. 1980). Furthermore, the CIA model generated a more 
acute disease in mice making it a less ideal surrogate for the chronic arthritic condition in 
humans.  
In order to create a more realistic and useful mouse model for RA, researchers 
explored the use of type II collagen antibodies (Terato et al. 1992). Evidence of elevated 
type II collagen antibody concentrations in the sera of RA patients suggested that type II 
collagen might drive the autoimmune response in RA (Trentham, Townes, and Kang 
1977). Collagen antibody-induced arthritis (CAIA) involves a combination of three to 
four type II collagen monoclonal antibodies (mAb). Although it is possible to induce 
arthritis with a single mAb, the duration of the disease was found to be longer and 
induction required a lower antibody dose when a combination of different collagen 
antibodies was used (Nandakumar and Holmdahl 2005). Following the induction of the 
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CAIA model, mice displayed both physical and histological evidence of arthritis similar 
to that observed in the CIA model and human rheumatoid arthritis (Figure 5) (Terato et 
al. 1992; Nandakumar, Svensson, and Holmdahl 2003).  
 
 
 
 
 
 
 
 
 
 
 
Certain strains of mice are more susceptible to CAIA, BALB/c mice are the most 
susceptible and C57BL/6 mice the least susceptible, however, strains that are CIA-
resistant are susceptible to CAIA which ultimately makes CAIA a more broadly 
applicable model than CIA (Nandakumar, Svensson, and Holmdahl 2003). Similar to the 
CIA model, CAIA generates an acute rather than chronic arthritic state, but the disease 
onset in CAIA is faster than that of CIA making it a more useful model in transgenic 
mice.  
 
Figure 5. A typical CAIA disease curve in BALB/c mice. Twelve mice were injected 
with a collagen mAb cocktail intravenously on day 0. An equal number of mice were 
injected with PBS as an internal control and a group of 10 mice were injected with a 
pair of irrelevant antibodies served as isotype antibody controls. All mice were scored 
for arthritis over 30 days (Nandakumar, Svensson, and Holmdahl 2003). 
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SPECIFIC AIMS 
 
In order to determine how the A2B adenosine receptor (A2BAR) modulates the expression 
of TNFα in the context of rheumatoid arthritis, we will: 
(1) Measure the effect of knocking out the A2BAR on systemic TNFα levels using ELISA 
assay on serum collected from mice at sacrifice. 
(2) Evaluate the effect of A2BAR on local expression of TNFα in mouse paw joints using 
immunohistochemistry. 
(3) Assess the effect of A2BAR knockout on TNFα, aggrecanase and MMP9 mRNA 
expression by RT-PCR analysis using RNA extracted from the mouse knee.    
 
We expect these studies will:  
(1) Elucidate the effect of A2BAR on the modulation of TNFα expression in mouse 
rheumatoid arthritis. 
(2) Provide evidence to support the interruption of A2BAR expression as a therapeutic 
strategy in combination with anti-TNFα therapy in the treatment of human rheumatoid 
arthritis.  
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METHODS 
 
Animals 
All of the animal experiments were conducted according to a protocol approved 
by the Institutional Animal Care and Use Committee (IACUC) at the Boston University 
School of Medicine in Boston, MA. A2BAR knockout (A2BAR KO) mice were bred onto 
a C57BL/6J background, along with wild-type (WT) mice of the same background.  
Induction of arthritis 
Arthritis was induced in four-month old female mice. A total of 64 mice were 
used in this study. The total enrollment was divided evenly into a treatment and a control 
group; 32 mice received a collagen antibody injection and the remaining 32 mice 
received a placebo injection. Within the treatment and control groups, the two genotypes 
were evenly represented with 16 A2BAR KO mice and 16 WT mice in each treatment 
group. Treated mice were injected with 6.25 mg (400µL) of collagen antibody 
(ArthritoMab, MDBiosciences, St. Paul, MN) on day one, followed by 100 µg (100µL) of 
lipopolysaccharide (LPS, Sigma-Aldrich, Saint Louis, MO) on day four. Control mice 
were injected with saline solution of the same respective volumes on days one and four. 
Mice were monitored and euthanized if their body weight decreased by more than 20%. 
Mice were sacrificed at day eight (36 mice of all four genotype/treatment combinations) 
and day ten (28 mice of all four genotype/treatment combinations) via CO2 asphyxiation 
and serum was collected immediately by cardiac puncture. The forepaws and hindpaws 
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were fixed in formaldehyde for histology and immunohistochemistry. The knees were 
harvested and frozen at -80°C for RNA extraction and RT-qPCR analysis.   
Immunohistochemistry 
Forepaws and hindpaws were decalcified in EDTA, embedded in paraffin and 
sectioned. Slides were selected based on tissue quality from each 
genotype/treatment/duration group were then processed for immunohistochemistry (IHC) 
targeting TNFα using a mouse monocolonal anti-TNFα antibody [52B83] (ab1793, 
Abcam, Cambridge, UK). A total of 26 slides were analyzed from 18 different animals. 
Of the 26 slides, 18 were from CAIA mice and 8 were from control mice. Within the 18 
CAIA slides, 13 represent A2BAR KO mice and 5 represent WT mice. The 8 control 
slides were evenly distributed among KO and WT genotypes. Both treatment durations 
were also represents with 10 day 8 specimens and 16 day 10 specimens. 
Antigen retrieval was by heat mediation (90°C for 20 minutes, 85°C for 10 
minutes) in rodent decloaker and samples were incubated with the primary anti- TNFα 
antibody (1:50 in PBS) overnight at 4°C. An undiluted 3,3' Diaminobenzidine (DAB) 
secondary antibody was used. All antibody staining was performed in an intelliPATH 
Automated Staining Instrument (Cat# IPS0001, Biocare Medical, Pacheco, CA).  
Slides were imaged using light microscopy and each slide was scored for presence 
or absence of TNFα staining in the cartilage, bone and synovium. Slides were scored 
blind to genotype, treatment and duration. The presence of TNFα was given a score of 1 
and the absence of TNFα was given a score of 0. Scores were assigned to each of the 
three tissues surrounding the joint.  
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RNA Extraction and Quantitative Real Time PCR analysis 
The knee joints from a total of 64 animals were harvested at day 8 and day 10, 
disarticulated into femoral and tibial components, immediately frozen in liquid nitrogen 
and stored at -80°C. Total RNA from the harvested mouse knees was isolated using 
QIAzol lysis reagent (Qiagen, Hilden, Germany). RNA purity and concentration were 
analyzed by NanoDrop Spectrophotometer (ND-1000, NanoDrop Technologies, 
Wilmington, DE) through evaluation of 260nm absorption and 260/280nm absorption 
ratio. The success of the RNA extractions was also evaluated by visual inspection after 
separation of total RNA on a 1.5% agarose gel.  
Two micrograms of RNA were reverse transcribed into complementary DNA 
(cDNA) using a Taqman Reverse Transcription kit (Applied Biosystems, Cat# 
N8080234). The cDNA was then used in real time-quantitative PCR (RT-qPCR) with 
Universal Master Mix (Applied Biosystems, Cat#4304437). Messenger RNA expression 
was determined for TNFα, aggrecanase (ADAMTS4) and matrix metalloproteinase 
(MMP9) using the following primers: TNFα ID: Mm00443258_m1, MMP9 ID: 
Mm00442991_m1, ADAMTS4 ID: Mm00556068_m1. RT-qPCR reactions for each 
target gene and an endogenous reference gene, 18s (ID: Mm03928990_g1), were 
performed in duplicate for 40 day 10 cDNA distributed across the 
treatment/genotype/knee component groups summarized in Table 2. 
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RT-qPCR reactions were performed in 20µL volumes. The cycling conditions 
were 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 s and 60°C for 1 min. All 
RT-qPCR reactions were performed with a ‘no-sample’ control. All the RT-qPCR 
primers used included a FAM fluorescein reporter and after the completion of the RT-
qPCR reaction, fluorescence data was obtained for each 96-well plate and the threshold 
cycle (CT) values for each sample were calculated.    
ELISA  
At the time of sacrifice at day 8 and day 10, blood samples were obtained from all 
64 enrolled animals by cardiac puncture following CO2 asphyxiation. The sera were 
isolated and frozen at -80°C until use. Sera concentrations of TNFα were measured by 
enzyme-linked immunosorbent assay (ELISA) with ELISA Ready-SET-Go! kit 
(eBioscience, San Diego, CA) according to the manufacturer’s protocol. Of the total 
serum samples collected (count: 64), only 59 samples were used in the ELISA assay due 
to the inadequate serum volume of the unused samples. ELISA analysis of the 59 samples 
Genotype/Treatment/Knee 
Component Group 
Number of cDNA Samples used in RT-
qPCR (n = 40) 
KO CAIA proximal knee 8 
KO CAIA distal knee 7 
KO Control proximal knee 8 
WT CAIA proximal knee 6 
WT CAIA distal knee 5 
WT Control proximal knee 6 
Table 2. Summary of cDNA sample distribution across genotype/treatment/knee 
component groups used in RT-qPCR analysis. 
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was duplicated in two separate assays and the samples were distributed across the 
treatment/genotype/duration groups summarized in Table 3. 
 
   
Genotype/Treatment/Duration 
Group 
Number of Serum Samples used in 
ELISA (n = 59) 
KO CAIA Day 8 7 
KO CAIA Day 10 8 
KO Control Day 8 7 
KO Control Day 10 8 
WT CAIA Day 8 8 
WT CAIA Day 10 7 
WT Control Day 8 10 
WT Control Day 10 4 
Table 3. Summary of sera sample distribution across genotype/treatment/duration 
groups used in ELISA analysis. 
	20 
RESULTS 
A2BAR KO CAIA mice exhibit greater TNFα expression at paw joints 
Immunohistochemistry showed that the pro-inflammatory cytokine TNFα was 
highly expressed in the cartilage and synovium of both A2BAR KO CAIA mice and WT 
CAIA mice compared to control mice (Figure 6). The presence of TNFα in the cartilage 
was comparable in KO CAIA and WT CAIA specimens from both treatment duration 
groups, day 8 and day 10, with 11/13 (85%) of all KO CAIA specimen positive for 
cartilage TNFα and 5/5 (100%) of all WT CAIA specimen positive for cartilage TNFα. 
Cartilage that is positive for the presence of TNFα is indicated with an asterisk (Figure 
6).  
Although rigorous quantification of TNFα by IHC was not performed, upon 
subjective visual inspection the KO CAIA paw joints displayed more robust TNFα 
staining than the WT CAIA paw joints across both treatment time points (Figure 6). 
Closer inspection of the cartilage finds the more robust TNFα staining observed in KO 
CAIA paw joints is consistent at the cellular level, with KO CAIA chondrocytes also 
exhibiting greater TNFα staining than WT CAIA chondrocytes (Figure 7, chondrocytes 
positive for TNFα are indicated by an arrowhead).  
Despite the near equivalent presence of TNFα in the cartilage of both KO CAIA 
and WT CAIA specimen, KO CAIA paw joints were more likely to present with TNFα in 
the subchondral bone (6/13, 46%) compared to WT CAIA paw joints (2/5, 40%) (Figure 
8, bone positive for TNFα is indicated by pound symbol). A similar comparison of TNFα 
presence in the synovial membrane surrounding the paw joints also finds 
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Figure 6. Comparison of mouse paw joints across 8 different genotype, 
treatment and duration groups stained by immunohistochemistry targeting TNFα 
using a mouse monocolonal anti-TNFα antibody [52B83] (ab1793, Abcam, 
Cambridge, UK). Tissue that is positive for TNFα appears brown and three 
different tissue types are marked for presence TNFα: arrowheads = cartilage, * = 
synovial membrane, # = bone.  
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Figure 7. Comparison of chondrocytes in mouse paw joints across 8 different 
genotype, treatment and duration groups stained by immunohistochemistry targeting 
TNFα using a mouse monocolonal anti-TNFα antibody [52B83] (ab1793, Abcam, 
Cambridge, UK). Tissue that is positive for TNFα appears brown. Arrowheads 
indicate chondrocytes positive for TNFα expression.  
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Figure 8. Comparison of mouse paw joints from an A
2
BAR KO mouse and a WT 
mouse both treated with collagen antibody (ArthritoMab) and LPS to induce an 
arthritic state over a 10 day period. Specimens were stained by immunohistochemistry 
targeting TNFα using a mouse monocolonal anti-TNF-alpha antibody [52B83] 
(ab1793, Abcam, Cambridge, UK). Tissue that is positive for TNFα appears brown and 
three different tissue types are marked for presence TNFα: arrowheads = cartilage, * = 
synovial membrane, # = bone. 
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KO CAIA specimen more likely to exhibit TNFα in the synovium (11/13, 85%) 
compared to WT CAIA specimen (4/5, 80%) (Figure 8, synovial membrane positive for 
TNFα is indicated by asterisk). 
A2BAR KO CAIA mice express highest TNFα concentration in sera 
Sera were collected by cardiac puncture at the time of sacrifice and bone harvest, 
8 or 10 days following the induction of arthritis. Serum TNFα production was only 
observed in KO CAIA mice at day 10 after induction of arthritis. The average serum 
TNFα concentration in KO CAIA at day 8 was 15.78 pg/mL and 92.81 pg/mL at day 10 
(Figure 9). In comparison, WT CAIA serum TNFα levels were insignificant with an 
average concentration of 9.55 pg/mL at day 8 and 11.89 pg/mL at day 10 (Figure 9). 
Control animals of both genotypes presented insignificant TNFα serum concentrations 
(Figure 9). 
 A2BAR KO CAIA mice have highest TNFα gene expression 
 RNA expression in CAIA and control mice of both KO and WT genotypes was 
examined in the proximal and distal knee joints at 10 days post CAIA induction. The fold 
change in gene expression was calculated ΔCT = 2
(-ddCT)
. Results are expressed as fold 
change ± SE for CAIA samples of both genotypes treated for 10 days. The distal knee of 
KO CAIA mice had the highest TNFα mRNA expression at day 10 expressing TNFα at a 
4.29 fold higher level than KO control mice (p-value = 0.05, Figure 10). 
	25 
 
 
The proximal knees of KO CAIA mice also had elevated TNFα mRNA expression at day 
10 expressing TNFα at a 3.16 fold higher level than KO control mice (Figure 10). WT 
CAIA mice express TNFα mRNA at greater levels than WT control mice, however, 
TNFα expression in both the proximal and distal knee of these mice (fold change of 1.31 
and 1.01, respectively) was less robust than the TNFα mRNA expression observed in KO 
CAIA mice (Figure 10). 
 
 
 
Figure 9. Serum TNFα production in A2BAR KO and WT mice. CAIA mice of both 
genotypes were injected with a collagen antibody and LPS to induced an arthritic state. 
Control mice were injected with saline. Sera collected by cardiac puncture at the time of 
sacrifice (day 8 or day 10) were assayed for TNFα by ELISA. Results are expressed as 
mean ± SEM of samples within each genotype/treatment/duration group for two 
independent ELISA experiments. 
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A2BAR KO CAIA mice have highest MMP-9 gene expression 
 RNA expression in CAIA and control mice of both KO and WT genotypes was 
examined in the proximal and distal knee joints at 10 days post CAIA induction. The fold 
change in gene expression was calculated ΔCT = 2
(-ddCT)
. Results are expressed as fold 
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Figure 10. TNFα gene expression in A2BAR KO and WT mice. CAIA mice of both 
genotypes were injected with a collagen antibody and LPS to induced an arthritic 
state. RNA was extracted from the proximal and distal components of the knee joint 
and converted to cDNA. cDNA was subjected to real-time quantitative PCR using a 
gene-specific primer for TNF (Mm00443258_m1,  Applied Biosystems). 18s 
(Mm03928990_g1, Applied Biosystems) served as the endogenous reference gene. 
The fold change in gene expression was calculated ΔCT = 2
(-ddCT)
. Results are 
expressed as fold change ± SE for CAIA samples of both genotypes treated for 10 
days. Asterisk represents statistical difference from control values (*, p = 0.05, 
ANOVA). 
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change ± SE for CAIA samples of both genotypes treated for 10 days. The distal knee of 
KO CAIA mice had the highest MMP-9 mRNA expression at day 10 expressing MMP-9 
at a 2.45-fold higher level than KO control mice (Figure 11). The proximal knee of KO 
CAIA mice also had significant MMP-9 mRNA expression at day 10 expressing MMP-9 
at a 2.27-fold higher level than KO control mice (Figure 11).  
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Figure 11. Matrix metalloproteinase-9 gene expression in A2BAR KO and WT mice. 
CAIA mice of both genotypes were injected with a collagen antibody and LPS to 
induced an arthritic state. RNA was extracted from the proximal and distal 
components of the knee joint and converted to cDNA. cDNA was subjected to real-
time quantitative PCR using a gene-specific primer for MMP9 (Mm00442991_m1, 
Applied Biosystems). 18s (Mm03928990_g1, Applied Biosystems) served as the 
endogenous reference gene. The fold change in gene expression was calculated ΔCT = 
2
(-ddCT)
. Results are expressed as fold change ± SE for CAIA samples of both 
genotypes treated for 10 days.  
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Although WT CAIA mice express MMP-9 mRNA at greater levels than WT control 
mice, MMP-9 expression in both the proximal and distal knee of these mice (fold change 
of 1.67 and 1.06, respectively) was less robust than the MMP-9 mRNA expression 
observed in KO CAIA mice (Figure 11). 
A2BAR WT CAIA mice have highest ADAMTS-4 gene expression 
 RNA expression in CAIA and control mice of both KO and WT genotypes was 
examined in the proximal and distal knee joints at 10 days post CAIA induction. The fold 
change in gene expression was calculated ΔCT = 2
(-ddCT)
. Results are expressed as fold 
change ± SE for CAIA samples of both genotypes treated for 10 days. The proximal knee 
of WT CAIA mice had the highest ADAMTS-4 mRNA expression at day 10 expressing 
ADAMTS-4 at a 9.16-fold higher level than WT control mice (p-value < 0.01, Figure 
12). The distal knee of WT CAIA mice also had increased ADAMTS-4 mRNA 
expression at day 10 expressing ADAMTS-4 at a 2.97-fold higher level than WT control 
mice (Figure 12). KO CAIA mice express ADAMTS-4 mRNA at greater levels than the 
KO control mice, however ADAMTS-4 expression in the proximal knee was 
insignificantly greater than KO control expression with a fold change of 1.65. KO CAIA 
expression of ADAMTS-4 in the distal knee was also low by comparison, but statistically 
significant, with an expression level 2.24-fold higher than KO control mice (p-value 
<0.05, Figure 12). 
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Figure 12. Aggrecanase (ADAMTS-4) gene expression in A2BAR KO and WT mice. 
CAIA mice of both genotypes were injected with a collagen antibody and LPS to 
induced an arthritic state. RNA was extracted from the proximal and distal 
components of the knee joint and converted to cDNA. cDNA was subjected to real-
time quantitative PCR using a gene-specific primer for ADAMTS-4 
(Mm00556068_m1, Applied Biosystems). 18s (Mm03928990_g1, Applied 
Biosystems) served as the endogenous reference gene. The fold change in gene 
expression was calculated ΔCT = 2
(-ddCT)
. Results are expressed as fold change ± SE 
for CAIA samples of both genotypes treated for 10 days. Asterisks represents 
statistical difference from control values (**, p < 0.05 and ***, p <0.01, ANOVA). 
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DISCUSSION 
A2BAR modulation of TNFα expression 
The primary focus of this study was the modulation of TNFα and expression of 
other cytokines by the A2B adenosine receptor in the context of rheumatoid arthritis. To 
study this receptor-cytokine interaction, a CAIA model was created in both A2BAR KO 
and WT mice. An arthritic condition was observed in CAIA mice of both genotypes and 
the absence of the A2BAR gene did not result in any observable differences in the gross 
arthritic state created in mice of each genotype (Mangano-Drenkard 2016). This suggests 
that the presence or absence of A2BAR does not effect the induction of an arthritic state 
nor did it directly influence bone and cartilage degradation.  
Despite the similarity in the induction of RA and gross evaluation of 
inflammation in the A2BAR KO and WT animals, the similarities did not extend to the 
level of cytokine expression. Immunohistochemistry staining revealed differences in the 
expression of TNFα in the synovial joints of KO CAIA and WT CAIA mouse paws. Paw 
joints from A2BAR KO CAIA mice exhibited more robust TNFα staining compared to 
WT CAIA specimens of the same treatment duration (Figure 8). Cartilage tissues were 
found to express TNFα in both genotypes; however, cartilage tissues in A2BAR KO 
CAIA mice had more robust TNFα in comparison to CAIA mice with intact A2B 
adenosine receptors (Figure 7). This finding is consistent with previous research that has 
found A2BAR KO mice have increased basal and LPS-stimulated TNFα release from 
macrophages and higher TNFα plasma levels (Ryzhov et al. 2008). The low-affinity 
A2BAR is known to mediate proinflammatory effects of adenosine by upregulating 
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cytokines and growth factor, however, there is evidence that a non-specific adenosine 
receptor agonist is capable of suppressing LPS-induced TNFα release in A2BAR KO 
macrophages, indicating that TNFα release is also mediated by other adenosine receptors 
(Ryzhov et al. 2008). Other studies have also found alternate adenosine receptors 
compensate for the role of A2BAR in KO models. One study found A2A and A3 
antagonists blocked the ability of NECA to inhibit LPS-induced release of TNFα and IL-
8 from synoviocytes, but this effect was not found for A1 or A2B antagonists (K. Varani et 
al. 2010). This finding provides further evidence that other members of the adenosine 
receptor family provide an alternative inflammatory pathway in the absence of the 
A2BAR. 
The elevated TNFα expression observed by immunohistochemistry in KO CAIA 
mice was validated by ELISA analysis of systemic expression of TNFα in serum. 
Significant serum production of TNFα was only observed in KO CAIA mice at day 10 
after induction of arthritis (Figure 9). Elevated systemic levels of TNFα in A2BAR KO 
animals have also been observed in the investigation of vascular injury (Chen et al. 
2011). In the wild-type environment, A2BAR elevates cAMP and suppresses TNFα levels 
at baseline and after vascular injury, which suggests that A2BAR has a protective role 
during inflammation. When A2BAR is ablated many cytokines, including TNFα, and 
extracellular matrix degradation enzymes were found in increased levels when an 
inflammatory state is initiated (Chen et al. 2011).  
In contrast to the results of the immunohistochemistry analysis, which showed 
comparable TNFα expression levels for day 8 and day 10 specimens of the same 
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genotype and treatment, ELISA analysis revealed a dramatic difference in the systemic 
expression of the cytokine depending on treatment duration. The average TNFα 
concentration in the sera of KO CAIA mice eight days post-arthritis induction was 15.78 
pg/mL, which is not significantly greater than the average TNFα concentration of control 
sera (Figure 9). In contrast, the average TNFα concentration in the sera of KO CAIA 
mice 10 days post-arthritis induction was 92.81 pg/mL. The significant difference in 
systemic TNFα concentration observed between day 8 and day 10 KO CAIA mice may 
be explained by the disease course typically observed in CAIA mice. Following induction 
of arthritis using the CAIA mAb cocktail, mice begin to develop inflammation within a 
few days of injection and the average arthritis score peaks between day 8 and day 10 
post-induction (Nandakumar, Svensson, and Holmdahl 2003). As the systemic expression 
of TNFα increases with the emergence of arthritis symptoms and mounting inflammation, 
it is reasonable that the sera collected from mice at day 10 express higher levels of TNFα 
compared to sera collected at day 8. A more recent study found that CAIA induced 
cytokines display a biphasic expression pattern with an acute spike in expression within 
24 hours of LPS injection followed by a return to baseline levels and then a second spike 
at days 5 and 13, which coincide with the onset of arthritis (Moore et al. 2014). Therefore 
the differences in the sera TNFα concentrations observed between KO CAIA mice of the 
two treatment durations groups is likely due to increasing systemic cytokine levels due to 
the progression of the arthritic disease state.  
Analysis of cytokine gene expression revealed that A2BAR KO CAIA mice have 
the highest TNFα gene expression compared to KO control mice (Figure 10). Previous 
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research has found that A2BAR protects against excessive production of inflammatory 
cytokines by macrophages and other cells, both at baseline and in response to LPS 
treatment (Yang et al. 2006). This research supports the present study, which revealed 
lower TNFα gene expression at the synovial joints of WT CAIA mice with intact A2B 
adenosine receptors. However, it is possible that A2BAR are associated with adenosine-
independent regulation of TNFα. Research performed on macrophages in the presence of 
ADA, which removes the possibility of endogenous adenosine activation, still found 
elevated basal levels of TNFα in A2BAR KO macrophages compared to WT cells 
(Ryzhov et al. 2008). In other words, the A2B receptors on WT macrophages were not 
activated by endogenous adenosine and therefore not likely to significantly inhibit the 
expression of TNFα. The increase in TNFα seen in A2BAR KO mice may represent a loss 
of other protein functions not related to adenosine signaling. The rearrangement of 
A2BAR-coupled proteins when the receptor is ablated may affect regulation of TNFα 
expression (Ryzhov et al. 2008). It is therefore possible that the A2BAR protein interact 
with other signaling pathways unrelated to adenosine. Although this evidence does not 
help to clarify the role of A2BAR in the context of the present study, it suggests that future 
research should focus on manipulating other proteins and receptors if the goal is to find 
novel therapeutic targets to interrupt the TNFα inflammatory pathway. 
Although A2BAR influences many pathways relevant to rheumatoid arthritis 
evidence from the literature indicates that other adenosine receptors, particularly the 
A2AAR, provide an alternate pathway in the absence of A2BAR. It has been shown that 
A2A and A3 antagonists prevent a non-specific adenosine receptor agonist from inhibiting 
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LPS-induced TNFα release. This same inhibitory effect is not observed when A1 and A2B 
antagonists are used (K. Varani et al. 2010). A1-, A2A- and A3-specific agonists also 
prevent or reduce swelling in arthritis models, indicating that these receptors may 
mitigate detrimental effects of A2BAR KO on inflammation (David L. Boyle et al. 2002; 
Cohen et al. 2005; Fishman et al. 2006; Cohen et al. 2004; Vincenzi et al. 2013; Ochaion 
et al. 2008). The involvement of other receptors in the inflammatory response may 
explain why ablation of the A2BAR alone did not affect the swelling response to CAIA.  
The increased cytokine expression found in KO CAIA mice set up the expectation 
that WT mice would fare better than A2BAR KO mice when subjected to CAIA, however 
the findings of collaborators have shown the severity of joint swelling and disease in 
mice of both genotypes is comparable. Ablation of A2BAR in mice had little effect on the 
degenerative changes in bone and cartilage associated with CAIA (Mangano-Drenkard 
2016). This suggests A2BAR does not independently mediate these changes and that it 
may be necessary to target multiple adenosine receptors to ameliorate the impact of 
inflammation in RA. 
A2BAR modulation of cartilage degradation enzymes 
The ablation of A2BAR also influenced the expression of matrix 
metalloproteinases, a family of enzymes that can degrade all components of the 
extracellular matrix. Many proteinases are expressed in joint tissues of RA patients and 
matrix metalloproteinases are believed to have a key role in joint destruction (Katia 
Varani et al. 2011). MMPs play a significant role in the onset and progression of RA 
through degradation of collagen and other extracellular matrix components surrounding 
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the joint. Another significant impact of MMPs, including MMP-9 specifically, is the 
promotion of angiogenesis, an essential part of RA pathogenesis. For angiogenesis to 
occur and reach the excessive levels observed in the RA disease state, the basement 
membrane and extracellular matrix must first be degraded to allow for the growth of new 
vessels. To this end, MMP-9 has been found in excessive levels in the joint tissues of RA 
patients and MMP-9 gene knockout mice are significantly less susceptible to arthritis 
(Kim et al. 2011). In this study, A2BAR KO CAIA mice had the highest MMP-9 mRNA 
expression at day 10 with a 2.45-fold higher level in the distal knee and a 2.27-fold 
higher expression level in the proximal knee compared to KO control mice (Figure 11). 
The higher MMP-9 expression observed in A2BAR KO mice indicates a relationship 
between the adenosine receptor and the enzyme. Evidence of this relationship was also 
presented in a study of macrophages in the context of vascular injury in which the 
absence of the A2BAR in activated macrophages was associated with increased MMP-9 
levels (Chen et al. 2011). This study also found elevated levels of TNFα, in combination 
with A2BAR ablation, resulted in the greatest stimulation of MMP-9 expression. The 
comparable conditions generated in the present study least to a similar conclusion that 
A2BAR activation may reduce MMP-9 expression and therefore play a protective role by 
inhibiting angiogenesis in RA pathogenesis.  
Aggrecancases (ADAMTS) are another family of proteolytic enzymes that play a 
significant role in the cartilage degradation that occurs in RA. ADAMTS4 expression is 
upregualted in arthritic disease and its mRNA expression in the synovial joint was 
measured in this study. Prior studies have failed to adequately characterize the sole 
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impact of ADAMTS4 in the cleavage of cartilage components and its activity seems 
closely linked with the proteolytic activity of ADAMTS5. In the context of osteoarthritis, 
ADAMTS4 upregulation was found to be dependent on IL-1 and TNFα expression and it 
is possible a similar expression pattern may exist in rheumatoid arthritis (Dancevic and 
McCulloch 2014). Due to their cooperative nature, it is difficult to decipher the different 
roles of the aggrecanase enzymes in RA pathogenesis; however, the evidence of 
inflammatory cytokine interactions suggests that ADAMTS4 may represent an important 
therapeutic target.  
In the present study, ADAMTS4 posed an exception to the trend of cytokine and 
enzyme upregulation in the A2BAR KO model. ADAMTS4 expression was highest in the 
WT model with a 9.16-fold higher expression level in the proximal knee of WT CAIA 
mice than WT control mice (p-value < 0.01, Figure 12). The distal knee of WT CAIA 
mice also had increased ADAMTS-4 mRNA expression at day 10 expressing ADAMTS-
4 at a 2.97-fold higher level than WT control mice, although this was not found to be 
statistically significant. By comparison, KO CAIA expression in both the proximal and 
distal knee was only marginally increased over the expression in KO control mice (1.65-
fold and 2.24-fold, respectively). Previous research has found that TNFα inhibition may 
lead to a reduction in aggrecanase activity, which may explain the slowed radiographic 
disease observed in patients treated with anti-TNFα therapies (Dancevic and McCulloch 
2014). The interaction established between TNFα and aggrecanase suggests that 
ADAMTS4 mRNA expression should be higher in mice with higher TNFα expression. In 
other words, the results of the ADAMTS4 gene expression assay are not consistent with 
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the other findings of this study and cannot be easily explained by the current body of 
research into aggrecanase expression in arthritic disease. To date the literature does not 
provide context for the observed interaction between ADAMTS4 and A2BAR expression, 
but it is clear from the results of this study that further investigation into the interaction 
between aggrecanases and adenosine receptors in warranted.   
Although MMP and ADAMTS enzymes are appealing targets for RA therapies, it 
is important to consider the crucial role many of these extracellular matrix enzymes play 
in cartilage remodeling and joint homeostasis. As damaging as these enzymes appear to 
be when they are in excess, a certain balance of anabolism and catabolism must be 
maintained within the joint for it to remain healthy and functional. When developing 
novel therapeutics to combat the damaging effects of cartilage degradation in arthritic 
diseases, a complete elimination of MMP and ADAMTS enzyme activity may not be the 
most prudent solution. 
Future Work 
 The goal of this study was to clarify the relationship between A2BAR and TNFα 
expression in mouse model of rheumatoid arthritis. Although the results of this study do 
allude to a modulatory effect of A2BAR on the expression of TNFα and other key 
molecules in RA pathogenesis, in the context of other research it is also clear that other 
adenosine receptors play a role as well. To expand on the findings of this study and 
further elucidate the roles of the different adenosine receptors, future research should 
undertake the study of A2A and A3ARs and the use of specific A2A and A3AR agonist to 
suppress the expression of inflammatory cytokines to ameliorate the symptoms of RA.  
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Prior research suggests that the activation of A2A and A3ARs suppresses proinflammatory 
cytokines (Katia Varani et al. 2011). A2AAR and A3AR are also upregulated in RA 
patients in comparison to healthy individuals, but A2BAR are expressed in similar levels 
between RA patients and healthy individuals. The upregulation of A2AAR and A3AR 
could represent compensatory mechanism to counteract the inflammatory status. In RA 
patients, the increase of A2AAR and A3AR density reflected an increase in receptor 
functionality suggesting a role of adenosine in the reduction of inflammatory status and 
in cartilage degradation induced by MMP activity and expression (Katia Varani et al. 
2011). Further exploration into the roles of A2AAR and A3AR in the protection of the 
joint from inflammatory pathology may lead to a more efficient means of treating RA 
through specific adenosine receptors.  
A2BAR ablation had no effect on the expression of mRNA encoding A2A receptors 
in peritoneal macrophages and on NECA-induced suppression of LPS-activated TNFα 
release (Ryzhov et al. 2008). Both A2A and A2B are known to stimulate adenylate cyclase, 
however recent research has found that NECA-induced cAMP accumulation was similar 
in peritoneal macrophages obtained from WT and A2BAR KO mice, indicating the 
dominant role of A2A in the stimulation of adenylate cyclase (Ryzhov et al. 2008). 
Adenosine analogs inhibit joint destruction when used in the treatment of adjuvant 
induced arthritis and septic arthritis (Boyle et al. 2002; Fishman et al. 2006).  
In RA patients, adenosine suppressed the elevated levels of pro-inflammatory cytokines 
such as TNFα and IL-1β (Forrest et al. 2005).  
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Clinical evidence in RA patients shows that treatment with A3 agonists lead to 
improvement in signs and symptoms. Furthermore, A3 agonists prevented cartilage 
damage, osteoclast/osteophyte formation, bone destruction and markedly reduced pannus 
formation and lymphocyte formation (Silverman et al. 2008). Research supports the use 
of A3AR as a therapeutic target and found that oral treatment with selective A3AR agonist 
CF101 resulted in a decrease in inflammation, pannus formation, cartilage destruction 
and bone resorption and lyses (Rath-Wolfson et al. 2006). The anti-inflammtory effect of 
A3AR has also been found in fibroblast-like synoviocytes derived from the synovial fluid 
of RA patients (Ochaion et al. 2008).  
Anti-rheumatic therapies, including anti-TNFα, target protein products that are 
expressed predominately by activated monocytes and macrophages. Unfortunately, these 
therapies are ineffective in many patients and lose their effectiveness over time 
suggesting that targeting TNFα-mediated inflammation is insufficient to fully address 
underlying mechanisms of disease progression. For this reason, it is important to 
understand the factors that contribute to the poor therapeutic response to anti-TNFα 
agents, including the involvement of the adenosine receptor pathway in RA. Adenosine 
receptor modulation of pro-inflammatory cytokines makes the receptors, including 
A2BAR, A2AAR, and A3AR, appealing targets for novel RA therapies.  
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